Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells

Subramanian,Romesh  R.; Yamakawa,Akio

doi:10.3892/ijo.2012.1602

Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells

Authors:
- Romesh R. Subramanian
- Akio Yamakawa
View Affiliations

Affiliations: Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
Published online on: August 22, 2012 https://doi.org/10.3892/ijo.2012.1602
Pages: 1855-1862

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Members of the Ras protooncogene family are mutated in approximately 75% of colon cancers. The Raf kinases (Raf-1, b-Raf and a-Raf) directly interact with Ras and serve as mediators of mitogenic signals. Expression of the constitutively active alleles of Raf or Ras gene families results in oncogenesis in a number of model systems. Previous studies emphasized the importance of Raf-1 and b-Raf in preventing apoptosis in addition to their roles in cell growth. In the present study, we examined whether inhibition of the Raf-1 or b-Raf kinase decreases cell growth and increases apoptosis in colon cancer cells. c-Raf and b-Raf were depleted in colon cancer cell lines, such as HCT116, HT29 and Colo205, containing Ras or b-Raf mutations by RNA interference (RNAi). The results showed that colon cancer cells with activating Ras mutations undergo apoptosis following Raf-1 inhibition, as determined by cell cycle analysis and the release of cytochrome c. Moreover, in b-Raf mutant colon cancers, the inhibition of b-Raf as compared to Raf-1 is crucial for cancer cell death. There is increasing evidence for both MEK-independent Raf signaling and Raf-independent MEK signaling. Thus, we investigated whether targeting multiple points of the mitogen-activated protein kinase (MAPK) pathway with a MEK inhibitor and Raf RNAi increases cancer cell death. The results showed that combination therapy, inhibiting Raf and MEK kinases simultaneously, increased apoptosis in colon cancer cells. Taken together, our data demonstrate that combination therapy targeting the MAPK pathway at two distinct points, Raf kinase and MEK, has greater efficacy in increasing cancer cell death and is likely to improve therapeutic outcomes for patients.

View Figures

View References

1.	Downward J: Ras signalling and apoptosis. Curr Opin Genet Dev. 8:49–54. 1998. View Article : Google Scholar
2.	Barbacid M: Ras genes. Annu Rev Biochem. 56:779–827. 1987. View Article : Google Scholar
3.	Kiaris H and Spandidos D: Mutations of ras genes in human tumours (Review). Int J Oncol. 7:413–421. 1995.
4.	Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Chong H, Vikis HG and Guan K-L: Mechanisms of regulating the Raf kinase family. Cell Signal. 15:463–469. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Storm SM, Brennscheidt U, Sithanandam G and Rapp UR: Raf oncogenes in carcinogenesis. Crit Rev Oncog. 2:1–8. 1990.
8.	Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Mikula M, Schreiber M, Husak Z, et al: Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 20:1952–1962. 2001. View Article : Google Scholar : PubMed/NCBI
10.	Wojnowski L, Zimmer AM, Beck TW, et al: Endothelial apoptosis in Braf-deficient mice. Nat Genet. 16:293–297. 1997. View Article : Google Scholar : PubMed/NCBI
11.	Wojnowski L, Stancato LF, Larner AC, Rapp UR and Zimmer A: Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev. 91:97–104. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 418:9342002. View Article : Google Scholar : PubMed/NCBI
13.	Britten RA, Perdue S, Opoku J and Craighead P: paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens. Radiother Oncol. 48:329–334. 1998. View Article : Google Scholar
14.	Rasouli-Nia A, Liu D, Perdue S and Britten RA: High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin Cancer Res. 4:1111–1116. 1998.PubMed/NCBI
15.	Huser M, Luckett J, Chiloeches A, et al: MEK kinase activity is not necessary for Raf-1 function. EMBO J. 20:1940–1951. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Murakami MS and Morrison DK: Raf-1 without MEK? Sci STKE. 2001:e302001.
17.	Nowell PC: The clonal evolution of tumor cell populations. Science. 194:23–28. 1976. View Article : Google Scholar : PubMed/NCBI
18.	Kinzler KW and Vogelstein B: Landscaping the cancer terrain. Science. 280:1036–1037. 1998. View Article : Google Scholar : PubMed/NCBI
19.	Jain M, Arvanitis C, Chu K, et al: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:102–104. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Felsher DW and Bishop JM: Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 4:199–207. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Pelengaris S, Littlewood T, Khan M, Elia G and Evan G: Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell. 3:565–577. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Chin L, Tam A, Pomerantz J, Wong M, et al: Essential role for oncogenic Ras in tumour maintenance. Nature. 400:468–472. 1999. View Article : Google Scholar : PubMed/NCBI
23.	Barbacid M: Ras oncogenes: their role in neoplasia. Eur J Clin Invest. 20:225–235. 1990. View Article : Google Scholar : PubMed/NCBI
24.	Anderson P: Kinase cascades regulating entry into apoptosis. Microbiol Mol Biol Rev. 61:33–46. 1997.PubMed/NCBI
25.	Rice PL, Goldberg RJ, Ray EC, Driggers LJ and Ahnen DJ: Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 61:1541–1547. 2001.PubMed/NCBI
26.	Bos JL, Fearon ER, Hamilton SR, et al: Prevalence of ras gene mutations in human colorectal cancers. Nature. 327:293–297. 1987. View Article : Google Scholar : PubMed/NCBI
27.	Zhou G and Kuo MT: NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem. 272:15174–15183. 1997.
28.	Zimmermann S, Rommel C, Ziogas A, Lovric J, Moelling K and Radziwill G: MEK1 mediates a positive feedback on Raf-1 activity independently of Ras and Src. Oncogene. 15:1503–1511. 1997. View Article : Google Scholar : PubMed/NCBI
29.	Harding A, Giles N, Burgess A, Hancock JF and Gabrielli BG: Mechanism of mitosis-specific activation of MEK1. J Biol Chem. 278:16747–16754. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Ley R, Balmanno K, Hadfield K, Weston C and Cook SJ: Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein. Bim. J Biol Chem. 278:18811–18816. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Sebolt-Leopold JS, Dudley DT, Herrera R, et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 5:810–816. 1999. View Article : Google Scholar : PubMed/NCBI
32.	Majewski M, Nieborowska-Skorska M, Salomoni P, et al: Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 59:2815–2819. 1999.PubMed/NCBI
33.	Fang X, Yu S, Eder A, et al: Regulation of BAD phosphorylation at serine 112 by the Rasmitogen-activated protein kinase pathway. Oncogene. 18:6635–6640. 1999. View Article : Google Scholar : PubMed/NCBI
34.	Zhong J, Troppmair J and Rapp UR: Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria. Oncogene. 20:4807–4816. 2001. View Article : Google Scholar : PubMed/NCBI
35.	Subramanian RR, Masters SC, Zhang H and Fu H: Functional conservation of 14-3-3 isoforms in inhibiting bad-induced apoptosis. Exp Cell Res. 271:142–151. 2001. View Article : Google Scholar : PubMed/NCBI
36.	Chen J, Fujii K, Zhang L, Roberts T and Fu H: Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA. 98:7783–7788. 2001. View Article : Google Scholar : PubMed/NCBI
37.	Baumann B, Weber CK, Troppmair J, et al: Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci USA. 97:4615–4620. 2000. View Article : Google Scholar : PubMed/NCBI
38.	Alessandrini A, Greulich H, Huang W and Erikson RL: Mek1 phosphorylation site mutants activate Raf-1 in NIH 3T3 cells. J Biol Chem. 271:31612–31618. 1996. View Article : Google Scholar : PubMed/NCBI